PURPOSE: Pegaspargase (PEG-ASP) has largely replaced native Escherichia coli asparaginase (L-ASP) in the treatment of acute lymphoblastic leukemia because of its longer half-life and lower immunogenicity. Risk factors for allergic reactions to PEG-ASP remain unclear. Here, we identify risk factors for reactions in a front-line acute lymphoblastic leukemia trial and assess the usefulness of serum antibodies for diagnosing allergy and predicting rechallenge outcome. PATIENTS AND METHODS: PEG-ASP was administered to 598 patients in St Jude's Total XVI study. Results were compared with Total XV study (ClinicalTrials.gov identifiers: NCT00549848 and NCT00137111), which used native L-ASP. Serum samples (n = 5,369) were analyzed for anti-PEG-ASP immunoglobulin G by enzyme-linked immunosorbent assay. Positive samples were tested for anti-polyethylene glycol (PEG) and anti-L-ASP. We analyzed potential risk factors for reactions and associations between antibodies and reactions, rechallenge outcomes, and PEG-ASP pharmacokinetics. RESULTS: Grade 2 to 4 reactions were less common in the Total XVI study with PEG-ASP (81 [13.5%] of 598) than in the Total XV study with L-ASP (169 [41.2%] of 410; P = 1.4 × 10-23). For Total XVI, anti-PEG, not anti-L-ASP, was the predominant component of anti-PEG-ASP antibodies (96%). In a multivariable analysis, more intrathecal therapy (IT) predicted fewer reactions (P = 2.4 × 10-5), which is consistent with an immunosuppressant contribution of IT. Anti-PEG-ASP was associated with accelerated drug clearance (P = 5.0 × 10-6). Failure of rechallenge after initial reactions was associated with anti-PEG-ASP (P = .0078) and was predicted by the occurrence of angioedema with first reaction (P = .01). CONCLUSION: Less IT therapy was the only independent clinical risk factor for reactions to PEG-ASP. PEG, and not L-ASP, is the major antigen that causes allergic reactions. Anti-PEG-ASP has utility in predicting and confirming clinical reactions to PEG-ASP as well as in identifying patients who are most likely to experience failure with rechallenge.
PURPOSE:Pegaspargase (PEG-ASP) has largely replaced native Escherichia coli asparaginase (L-ASP) in the treatment of acute lymphoblastic leukemia because of its longer half-life and lower immunogenicity. Risk factors for allergic reactions to PEG-ASP remain unclear. Here, we identify risk factors for reactions in a front-line acute lymphoblastic leukemia trial and assess the usefulness of serum antibodies for diagnosing allergy and predicting rechallenge outcome. PATIENTS AND METHODS: PEG-ASP was administered to 598 patients in St Jude's Total XVI study. Results were compared with Total XV study (ClinicalTrials.gov identifiers: NCT00549848 and NCT00137111), which used native L-ASP. Serum samples (n = 5,369) were analyzed for anti-PEG-ASP immunoglobulin G by enzyme-linked immunosorbent assay. Positive samples were tested for anti-polyethylene glycol (PEG) and anti-L-ASP. We analyzed potential risk factors for reactions and associations between antibodies and reactions, rechallenge outcomes, and PEG-ASP pharmacokinetics. RESULTS: Grade 2 to 4 reactions were less common in the Total XVI study with PEG-ASP (81 [13.5%] of 598) than in the Total XV study with L-ASP (169 [41.2%] of 410; P = 1.4 × 10-23). For Total XVI, anti-PEG, not anti-L-ASP, was the predominant component of anti-PEG-ASP antibodies (96%). In a multivariable analysis, more intrathecal therapy (IT) predicted fewer reactions (P = 2.4 × 10-5), which is consistent with an immunosuppressant contribution of IT. Anti-PEG-ASP was associated with accelerated drug clearance (P = 5.0 × 10-6). Failure of rechallenge after initial reactions was associated with anti-PEG-ASP (P = .0078) and was predicted by the occurrence of angioedema with first reaction (P = .01). CONCLUSION: Less IT therapy was the only independent clinical risk factor for reactions to PEG-ASP. PEG, and not L-ASP, is the major antigen that causes allergic reactions. Anti-PEG-ASP has utility in predicting and confirming clinical reactions to PEG-ASP as well as in identifying patients who are most likely to experience failure with rechallenge.
Authors: C Liu; J D Kawedia; C Cheng; D Pei; C A Fernandez; X Cai; K R Crews; S C Kaste; J C Panetta; W P Bowman; S Jeha; J T Sandlund; W E Evans; C-H Pui; M V Relling Journal: Leukemia Date: 2012-04-09 Impact factor: 11.528
Authors: Naomi Winick; Meenakshi Devidas; Si Chen; Kelly Maloney; Eric Larsen; Leonard Mattano; Michael J Borowitz; Andrew Carroll; Julie M Gastier-Foster; Nyla A Heerema; Cheryl Willman; Brent Wood; Mignon L Loh; Elizabeth Raetz; Stephen P Hunger; William L Carroll Journal: J Clin Oncol Date: 2017-05-23 Impact factor: 44.544
Authors: A Thyss; S Suciu; Y Bertrand; F Mazingue; A Robert; E Vilmer; F Mechinaud; Y Benoit; P Brock; A Ferster; P Lutz; P Boutard; G Marguerite; E Plouvier; G Michel; D Plantaz; M Munzer; X Rialland; J M Chantraine; L Norton; G Solbu; N Philippe; J Otten Journal: J Clin Oncol Date: 1997-05 Impact factor: 44.544
Authors: C A Fernandez; E Stewart; J C Panetta; M R Wilkinson; A R Morrison; F D Finkelman; J T Sandlund; C H Pui; S Jeha; M V Relling; P K Campbell Journal: Cancer Chemother Pharmacol Date: 2014-04-27 Impact factor: 3.333
Authors: Michael S Hershfield; Nancy J Ganson; Susan J Kelly; Edna L Scarlett; Denise A Jaggers; John S Sundy Journal: Arthritis Res Ther Date: 2014-03-07 Impact factor: 5.156
Authors: John C Panetta; Yiwei Liu; Hope D Swanson; Seth E Karol; Ching-Hon Pui; Hiroto Inaba; Sima Jeha; Mary V Relling Journal: Pediatr Blood Cancer Date: 2020-04-23 Impact factor: 3.167
Authors: Emily R Finch; Colton A Smith; Wenjian Yang; Yiwei Liu; Nancy M Kornegay; John C Panetta; Kristine R Crews; Alejandro R Molinelli; Cheng Cheng; Deqing Pei; Laura B Ramsey; Seth E Karol; Hiroto Inaba; John T Sandlund; Monika Metzger; William E Evans; Sima Jeha; Ching-Hon Pui; Mary V Relling Journal: Pediatr Blood Cancer Date: 2019-10-14 Impact factor: 3.167
Authors: David O Riley; Jenna M Schlefman; Hans Christoph Vitzthum Von Eckstaedt V; Amy L Morris; Michael K Keng; Firas El Chaer Journal: Curr Hematol Malig Rep Date: 2021-05-12 Impact factor: 3.952
Authors: Hope D Swanson; John C Panetta; Patricia J Barker; Yiwei Liu; Hiroto Inaba; Mary V Relling; Ching-Hon Pui; Seth E Karol Journal: Blood Date: 2020-01-02 Impact factor: 22.113
Authors: Meilyn Sylvestre; Shixian Lv; Lucy F Yang; Nicholas Luera; David J Peeler; Bing-Mae Chen; Steve R Roffler; Suzie H Pun Journal: J Control Release Date: 2021-01-11 Impact factor: 9.776
Authors: Yiwei Liu; John C Panetta; Wenjian Yang; Seth E Karol; Cheng Cheng; Jun J Yang; William E Evans; Hiroto Inaba; Ching-Hon Pui; Sima Jeha; Mary V Relling Journal: Blood Date: 2020-12-17 Impact factor: 22.113
Authors: Matthew Greenhawt; Elissa M Abrams; Marcus Shaker; Derek K Chu; David Kahn; Cem Akin; Waleed Alqurashi; Peter Arkwright; James L Baldwin; Moshe Ben-Shoshan; Jonathan Bernstein; Theresa Bingeman; Katerina Blumchen; Aideen Byrne; Antonio Bognanni; Dianne Campbell; Ronna Campbell; Zain Chagla; Edmond S Chan; Jeffrey Chan; Pasquale Comberiatti; Timothy E Dribin; Anne K Ellis; David M Fleischer; Adam Fox; Pamela A Frischmeyer-Guerrerio; Remi Gagnon; Mitchell H Grayson; Caroline C Horner; Johnathan Hourihane; Constance H Katelaris; Harold Kim; John M Kelso; David Lang; Dennis Ledford; Michael Levin; Jay Lieberman; Richard Loh; Doug Mack; Bruce Mazer; Gissele Mosnaim; Daniel Munblit; S Shahzad Mustafa; Anil Nanda; John Oppenheimer; Kirsten P Perrett; Allison Ramsey; Matt Rank; Kara Robertson; Javed Shiek; Jonathan M Spergel; David Stukus; Mimi Lk Tang; James M Tracy; Paul J Turner; Anna Whalen-Browne; Dana Wallace; Julie Wang; Susan Wasserman; John K Witty; Margitta Worm; Timothy K Vander Leek; David Bk Golden Journal: J Allergy Clin Immunol Pract Date: 2021-06-18